AMLX Amylyx Pharmaceuticals
- 1.930
- +0.120+6.63%
- 1.929
- -0.001-0.04%
Amylyx Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Express News | Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) released interim data from the ongoing Phase 2 HELIOS trial of AMX0035 for Wolfram syndrome.
Amylyx Down 6% Despite Encouraging Phase 2 Data on Rare Disorder Drug
Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metab
Amylyx Pharmaceuticals To Host Virtual Webcast To Discuss Interim Data From Phase 2 HELIOS Study Of AMX0035 In Wolfram Syndrome On April 10, 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of th
Unveiling 6 Analyst Insights On Amylyx Pharma
In the last three months, 6 analysts have published ratings on Amylyx Pharma (NASDAQ:AMLX), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick overvi
Express News | HC Wainwright & Co. Maintains Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 205.34% HC Wainwright & Co. $8 → $8 Maintains Buy 03/12/2024 205.34% HC Wainwright & Co. $42 →
Amylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impact
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are More Bearish Than They Used To Be
One thing we could say about the analysts on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts fo
Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating
Amylyx Pharmaceuticals (AMLX) has an average rating of Hold and price targets ranging from $3 to $8, according to analysts polled by Capital IQ. Price: 2.59, Change: -0.02, Percent Change: -0.96
Amylyx Pharmaceuticals Hold Rating: Navigating Setbacks With a Strategic Pivot and Long-Term Potential
Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developments
Analysis
Price Target
No Data
